Medicare’s moment of truth on a potential blockbuster cancer therapy is rapidly approaching.
The Centers for Medicare & Medicaid Services are slated to decide by the end of May whether to cover CAR T-cell therapy for all program enrollees.
The treatment, which can take several weeks and cost up to $1 million, is a new option for people with leukemia and lymphoma. It requires extracting and then genetically engineering a patient’s immune system T-cells in a lab, multiplying the modified cells, and then putting them back into the body to attack the cancerous cells.
Medicare contractors currently decide whether to...
For more stories, analysis and expertiseOR Request Trial